Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Maryland Observer.
Press releases published on July 2, 2025

PropertyRoom.com Offers Collectors a Chance at a Legendary 1966 Amphicar 770
FREDERICK, MD, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- PropertyRoom.com the leading online police auction site for seized, surplus, and unique collectibles, announced today it will auction a rare 1966 Amphicar 770 this July. Known as one of the …

BTR: SMB Leaders Must Balance Innovation and Risk to Navigate AI Era
SILVER SPRING, MD, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- The AI revolution is no longer confined to the Fortune 500. With copilots, chatbots, and machine learning tools becoming increasingly accessible through mainstream productivity suites …

National Security Capital Advisors Serves as Exclusive Financial Advisor in the Sale of Riverstone Enterprise Solutions
COLUMBIA, MD, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- National Security Capital Advisors LLC (“NSCA”) is pleased to announce that it has acted as the exclusive financial advisor to Riverstone Enterprise Solutions, LLC (“RES”) in its recent sale …

APV Expands HHS Partnership to Drive Innovation in Salesforce-Powered Claims System
APV enters the next phase after delivering a federal claims system in Salesforce, focusing on innovation, AI, and long-term support. COLUMBIA, MD, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- APV, a woman-owned leader in mission-driven digital …

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
GAITHERSBURG, Md., July 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the expansion of its proprietary NARCANDirect® online distribution network to include KLOXXADO® (naloxone HCl) Nasal Spray 8 mg. The platform …

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on …

Central Texas Regional Mobility Authority Extends Rekor Command® Contract in $1.4 Million Agreement to Enhance Toll Road Traffic Operations
COLUMBIA, Md. , July 02, 2025 (GLOBE NEWSWIRE) -- Rekor Systems, Inc. (NASDAQ: REKR) (the "Company), a leader in developing and implementing state-of-the-art roadway intelligence technology, today announced the extension of its Rekor Command® contract with …